innovation to commercialization
DESCRIPTION
December 8th 2010: The 6th annual Dutch Life Sciences and Health conference was held in de Beurs van Berlage, Amsterdam. Willem de Laat, Managing Director at Life Sciences Health, talks about 'Innovation to commercialization'.TRANSCRIPT
![Page 1: Innovation to commercialization](https://reader038.vdocuments.mx/reader038/viewer/2022102805/554b01e7b4c905c12d8b4e0e/html5/thumbnails/1.jpg)
From innovation to commercialization
Willem de Laat
Managing Director
Life Sciences & Health
8 December 2010
![Page 2: Innovation to commercialization](https://reader038.vdocuments.mx/reader038/viewer/2022102805/554b01e7b4c905c12d8b4e0e/html5/thumbnails/2.jpg)
From innovation to commercialization
![Page 3: Innovation to commercialization](https://reader038.vdocuments.mx/reader038/viewer/2022102805/554b01e7b4c905c12d8b4e0e/html5/thumbnails/3.jpg)
Global biomedical trends
1 Trillion $ sales in 2014
150 billion $ patent expirations
Ongoing consolidation
75% diseases without cure
Healthy ageing
Strong R&D investment
• Ref.: Scrip News, April 2010
![Page 4: Innovation to commercialization](https://reader038.vdocuments.mx/reader038/viewer/2022102805/554b01e7b4c905c12d8b4e0e/html5/thumbnails/4.jpg)
1. Roche - $8.7B2. Pfizer - $7.4B3. Novartis - $7.06B4. Johnson & Johnson - $6.66B5. Sanofi-Aventis - $6.25B6. GlaxoSmithKline - $5.59B7. Merck - $5.58B8. Takeda Pharmaceuticals - $4.64B
9. AstraZeneca - $4.23B 10. Eli Lilly - $4.13B11. Bristol-Myers Squibb - $3.48B12. Boehringer Ingelheim - $3.03B13. Abbott Laboratories - $2.61B14. Daiichi Sankyo - $1.89B15. Astellas Pharma - $1.63B
Global R&D spending
![Page 5: Innovation to commercialization](https://reader038.vdocuments.mx/reader038/viewer/2022102805/554b01e7b4c905c12d8b4e0e/html5/thumbnails/5.jpg)
Health-related life sciences: an important sector in the Dutch economy
Drugs
Diagnostics
Devices
Companies Revenues FTE
Other
Total
Source: EIM study for EZ [2006], Voorstel LSG [2006]Preliminary data Biotech Outlook 2011
430
390
75
935
40
12.0 bn
2.7 bn
0.6 bn
15.7 bn
0.4 bn
37,000
12,000
54,600
3,400
± 150 companies highly innovative
Update 2010: >200 companies highly innovative
3% of GDP
2,200
![Page 6: Innovation to commercialization](https://reader038.vdocuments.mx/reader038/viewer/2022102805/554b01e7b4c905c12d8b4e0e/html5/thumbnails/6.jpg)
The Dutch life sciences and health innovation cluster builds upon a strong knowledge base
Excellent biobanks and ‘real life’ datainfrastructure
120 mile radius
Global players & very high
concentration of SMEs
Excellentuniversities
![Page 7: Innovation to commercialization](https://reader038.vdocuments.mx/reader038/viewer/2022102805/554b01e7b4c905c12d8b4e0e/html5/thumbnails/7.jpg)
5 of the top 10 European biotech deals are with Dutch companies, with a total value exceeding USD 2 billion
![Page 8: Innovation to commercialization](https://reader038.vdocuments.mx/reader038/viewer/2022102805/554b01e7b4c905c12d8b4e0e/html5/thumbnails/8.jpg)
But....the consolidation changing environment has impact on the Netherlands
Organon Solvay Crucell
![Page 9: Innovation to commercialization](https://reader038.vdocuments.mx/reader038/viewer/2022102805/554b01e7b4c905c12d8b4e0e/html5/thumbnails/9.jpg)
Life Sciences & Health Innovation ProgramImproving the investment and innovation climate in the Dutch life sciences and health sector
Hier komt een screenshot van de homepage 7 dec
5000+ unique visitors/month
Database forsubsidies and funding
Benchmark study on clinical trial performance to map the competitive
position of the Netherlands
Bio International Convention, Chicago, 2010
BIOBIO--EEUROPEUROPE SSPRINGPRING
MARCH 14-16, 2011, MARCH 14-16, 2011, MILAN, ITALYMILAN, ITALY
Thomson Pharma
![Page 10: Innovation to commercialization](https://reader038.vdocuments.mx/reader038/viewer/2022102805/554b01e7b4c905c12d8b4e0e/html5/thumbnails/10.jpg)
Biotech Outlook 2011 will be launched in Q1 next year
Improved cluster assessment method • Cluster size, output & investments• Context with major events• Comparison with international clusters
Cooperation with international academicinstitutes
Cooperation on methodology with Council of European BioRegions
Progress
![Page 11: Innovation to commercialization](https://reader038.vdocuments.mx/reader038/viewer/2022102805/554b01e7b4c905c12d8b4e0e/html5/thumbnails/11.jpg)
Sector vision
300 downloads
![Page 12: Innovation to commercialization](https://reader038.vdocuments.mx/reader038/viewer/2022102805/554b01e7b4c905c12d8b4e0e/html5/thumbnails/12.jpg)
“TOPGEBIED LIFE SCIENCES”We have to Build, Nurture and Promote it together
Health &
Wealth
![Page 13: Innovation to commercialization](https://reader038.vdocuments.mx/reader038/viewer/2022102805/554b01e7b4c905c12d8b4e0e/html5/thumbnails/13.jpg)
FEN-PHEN CASE (Wyeth)
Primary Pulmonary Hypertension on anti-obesity drug62 deaths before label change (1994)First court case (Billiton, Texas) $20 million20,000 claims < 1 monthDiscovery / browser /20,000 emailsWyeths prior knowledge exposedFirst settlement $1 billionReservations in Liability reserve fund total $21 billionStockprice decreased 50%
![Page 14: Innovation to commercialization](https://reader038.vdocuments.mx/reader038/viewer/2022102805/554b01e7b4c905c12d8b4e0e/html5/thumbnails/14.jpg)
www.lifescienceshealth.com